STOCK TITAN

Alkermes plc. (ALKS) SEC Filings, Jul-Aug 2026

ALKS NASDAQ

Alkermes plc filings document a Nasdaq-listed Irish public limited biopharmaceutical company focused on neuroscience medicines. The record includes 8-K reports for operating results, financial expectations, investor presentations, material definitive agreements and Regulation FD disclosures, along with proxy materials for annual general meeting matters, director elections, executive compensation and shareholder voting.

Capital-structure disclosures cover ordinary shares listed under ALKS and senior secured term loan facilities used in connection with completed acquisition activity. Material-event reports also address governance and executive transition matters, compensatory arrangements, commercial-product performance and clinical-stage disclosures for the company’s orexin 2 receptor agonist programs.

Rhea-AI Summary

Nancy Lynn Snyderman, a director of Alkermes plc, exercised fully vested non-qualified stock options to acquire 44,472 Ordinary Shares at an exercise price of $46.72 per share on August 3, 2026. She then sold 44,472 shares at a weighted average price of $50.3480 per share, in transactions priced between $50.07 and $50.70. Following these transactions, 20,783 Ordinary Shares are held indirectly through the Nancy Lynn Snyderman Revocable Trust.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
insider
-
Rhea-AI Summary

Alkermes plc. executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, exercised employee stock options for a total of 5,000 ordinary shares at exercise prices of $19.34 and $24.59, and on 2026-08-03 sold 9,000 ordinary shares at $48.58 per share. These option exercises and the share sale were effected pursuant to a Rule 10b5-1 trading plan adopted on 3/14/2025, and the exercised options were fully vested.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
insider
-
Rhea-AI Summary

On 2026-08-03, Alkermes plc executive David Joseph Gaffin, EVP and CLO, sold 2,034 Ordinary Shares of Alkermes at an average price of $48.58 per share. The sale, reported as a sale in the open market or a private transaction, was executed under a Rule 10b5-1 trading plan adopted on 11/19/2025, and he now directly holds 225,456 Ordinary Shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
insider
Rhea-AI Summary

Alkermes plc. officer Nancy Snyderman reported a proposed sale of 44,472 common shares, with an aggregate market value of $2,239,076.49 and an approximate sale date of August 3, 2026. The shares were acquired through exercise of employee stock options, with payment described as a broker assisted cashless sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
other
-
Rhea-AI Summary

Alkermes plc insider David Gaffin plans potential sales of Alkermes common stock through Merrill Lynch, with an aggregate market value of $98,811.72 and reference to 167,763,272 shares outstanding as of 08/03/2026. The shares relate to prior restricted stock unit and performance share unit awards granted under the issuer’s equity compensation plan that vested between 2014 and 2016. Gaffin has also reported multiple open-market sales of 2,034 shares each month from April through July 2026, with gross proceeds ranging from $70,315.38 to $109,897.02.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
other
-
Rhea-AI Summary

Craig Hopkinson, an affiliate of Alkermes plc, plans to sell 9,000 ordinary shares through Merrill Lynch on August 3, 2026, with an estimated aggregate value of $437,220.00. The shares derive from an employee stock option exercise and vesting of performance and restricted stock awards. The filing also lists five prior open-market sales of 9,000 shares each month from March through July 2026, with proceeds between $267,485.14 and $463,620.68.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
other
Rhea-AI Summary

Alkermes plc is elevating Blair C. Jackson, currently Executive Vice President and Chief Operating Officer, to serve as President and Chief Executive Officer effective August 1, 2026, and appointing him to its board of directors and the Financial Operating Committee, increasing the board size from nine to ten directors.

In his new role, Mr. Jackson will receive an annual base salary of $900,000 and a target annual cash performance award equal to 100% of base salary, with an award range of 0% to 200%. He will be granted a one-time promotion equity award with an aggregate target value of $5,000,000, split between performance-vesting restricted stock units with a three-year performance period and time-vesting stock options vesting over four years, plus a one-time special incentive performance stock option award with an aggregate target value of $3,000,000 that vests in two tranches based on share-price hurdles and at least two years of service. A new employment agreement provides severance and change-in-control protections, including cash payments based on multiples of salary and prior incentives and continued health benefits. He will not receive additional compensation for board or committee service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
current report
-
Rhea-AI Summary

Alkermes plc reported strong top-line growth for the quarter ended June 30, 2026, with total revenues of 496,009 thousand, up from 390,657 thousand a year earlier, but net income declined to 501 thousand from 87,098 thousand as expenses and interest rose.

For the first six months of 2026, revenues grew to 888,920 thousand from 697,167 thousand, while results swung to a net loss of 65,979 thousand, compared with net income of 109,562 thousand in 2025, largely reflecting the February 2026 acquisition of Avadel Pharmaceuticals.

The Avadel transaction carried preliminary consideration of 2,306,920 thousand, added 1,794,900 thousand of identifiable intangibles and 511,246 thousand of goodwill, and was financed with new term loans totaling 1,525,000 thousand, driving interest expense of 46,817 thousand and negative operating cash flow of 20,560 thousand year to date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.23%
Tags
quarterly report
-
Rhea-AI Summary

Alkermes plc reported Q2 2026 total revenues of $496.0 million, compared with $390.7 million a year earlier, driven by proprietary net sales of $411.7 million, including VIVITROL $124.5 million, ARISTADA $96.7 million, LYBALVI $94.0 million and newly acquired LUMRYZ $96.6 million.

GAAP net income for the quarter was $0.5 million versus $87.1 million in Q2 2025, reflecting higher R&D and SG&A, $22.6 million of amortization of acquired intangibles and a $26.4 million increase in contingent consideration tied to the Avadel acquisition. Adjusted EBITDA was $139.2 million, compared with $126.5 million.

At June 30, 2026, cash, cash equivalents and investments were $691.6 million, alongside a larger asset base following the Avadel transaction. Full‑year 2026 revenue and product‑level net sales guidance were reaffirmed, but GAAP net loss expectations were widened to $95–$115 million and EBITDA guidance reduced to $75–$95 million, while Adjusted EBITDA guidance remained $370–$410 million. Blair Jackson is scheduled to become CEO on August 1, 2026, with current CEO Richard Pops continuing as chairman.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.23%
Tags
current report
Rhea-AI Summary

Alkermes plc terminated its Authorized Generic Product Supply Agreement with Amneal Pharmaceuticals LLC on July 6, 2026. The agreement had allowed Amneal to distribute a limited quantity of an authorized generic version of VIVITROL in the United States for a one-year term tied to a third-party ANDA product launch.

The arrangement provided Alkermes Pharma Ireland Limited with payment at a premium to fully burdened manufacturing cost plus a share of any net profits from sales. After Alkermes notified Amneal that certain terms were not met and allowed time to remedy, Amneal informed Alkermes that it did not wish to order any batches.

Alkermes did not incur any penalties from ending the agreement, and no further payments or obligations are owed by either party. Both sides also agreed to release all claims against each other and their affiliates related to the agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
current report

FAQ

How many Alkermes plc. (ALKS) SEC filings are available on StockTitan?

StockTitan tracks 132 SEC filings for Alkermes plc. (ALKS), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Alkermes plc. (ALKS)?

The most recent SEC filing for Alkermes plc. (ALKS) was filed on November 12, 2026.